Trial Profile
A randomized open-label study to compare safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus that do not reach adequate glycemic control on their current sulfonylurea monotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Insulin suspension isophane
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms BENEFIT
- Sponsors Novartis Pharmaceuticals
- 19 Sep 2014 Primary endpoint has not been met (Percentage of patients reaching HbA1c below 7.0% without confirmed hypoglycaemia and weight gain), according to the results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.